Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Nov;75(11):1471-1480.
doi: 10.1007/s00228-019-02730-0. Epub 2019 Aug 3.

m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis

Maryam Ghadimi  1 , Zinat Mohammadpour  2 , Simin Dashti-Khavidaki  3   4 , Alireza Milajerdi  5
Affiliations
Meta-Analysis

m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis

Maryam Ghadimi et al. Eur J Clin Pharmacol. 2019 Nov.

Abstract

Purpose: Although there is controversy, some evidences proposed increased risk of post-transplant Pneumocystis carinii pneumonia (PCP) in patients receiving mammalian target of rapamycin (mTOR) inhibitors. This study aimed to examine the association between m-TOR inhibitors and the risk of developing PCP in solid organ transplant (SOT) recipients.

Methods: A comprehensive search was performed to find the eligible studies that investigated the incidence of PCP in patients treated with mTOR inhibitors after SOT. Random effect model was applied for meta-analysis.

Results: Combination of 15 effect sizes showed a significant positive association between mTOR inhibitor administration and the risk of PCP (OR = 1.90, 95%CIs = 1.44, 2.75). There was no heterogeneity between studies (I2 = 3.5%). Subgroup analysis revealed increased risk of PCP after the first year of transplantation (P < 0.001).

Conclusion: In conclusion, administration of mTOR inhibitors is a potential risk factor for late-onset PCP after SOT. Targeted PCP prophylaxis based on recipients' risk factors rather universal prophylaxis may lessen the risk.

Keywords: Everolimus; Meta-analysis; Pneumocystis pneumonia; Sirolimus; Solid organ transplant; mTOR inhibitors.

PubMed Disclaimer

References

    1. Gordon SM, LaRosa SP, Arroliga AC, Avery RK, Longworth DL (1999) Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 28:240–246. https://doi.org/10.1086/515126 - DOI - PubMed
    1. Kramer MR, Stoehr C, Lewiston NJ, Starnes VA, Theodore J (1992) Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation--how effective and for how long? Transplantation 53:586–589 - DOI
    1. Rodriguez M, Fishman JA (2004) Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 17:770–782. https://doi.org/10.1128/CMR.17.4.770-782.2004 - DOI - PubMed - PMC
    1. Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052–1059. https://doi.org/10.4065/82.9.1052 - DOI - PubMed
    1. Stern A, Green H, Paul M, Vidal L, Leibovici L (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 1:1–66. https://doi.org/10.1002/14651858.CD005590.pub3 - DOI

MeSH terms

Substances

LinkOut - more resources